In contrast, post-treatment evaluation of PD-L1 and Her-2/neu expression in the patient’s primary tumor showed 5% PD-L1 expression (CPS) (Figure 4d) and an Her-2/neu status of 0 (IHC) (Figure 4e) with an Her-2/neu/CEP17 ratio of 1.63 (FISH; Figure 4f). This evidence concerns the gene ERBB2 and neoplasm.